Qiagen (NYSE:QGEN) Receives Equal Weight Rating from Morgan Stanley

Morgan Stanley reiterated their equal weight rating on shares of Qiagen (NYSE:QGEN) in a research report sent to investors on Monday morning, Marketbeat reports. The firm currently has a $48.00 price objective on the stock, down from their previous price objective of $50.00.

Several other equities analysts have also recently weighed in on the company. Hsbc Global Res raised Qiagen to a “hold” rating in a report on Thursday, October 17th. Jefferies Financial Group reissued a “buy” rating and issued a $54.00 target price (up previously from $42.00) on shares of Qiagen in a report on Tuesday, December 10th. Finally, HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a research note on Thursday, October 17th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.50.

Qiagen Stock Performance

Shares of QGEN stock opened at $44.78 on Monday. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. The company has a 50 day moving average price of $43.81 and a 200-day moving average price of $43.84. Qiagen has a 52 week low of $39.03 and a 52 week high of $47.44. The firm has a market capitalization of $10.22 billion, a PE ratio of 114.82, a P/E/G ratio of 3.52 and a beta of 0.37.

Hedge Funds Weigh In On Qiagen

A number of hedge funds have recently modified their holdings of QGEN. Massmutual Trust Co. FSB ADV grew its position in shares of Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after purchasing an additional 243 shares in the last quarter. CWM LLC grew its holdings in Qiagen by 11.5% during the 3rd quarter. CWM LLC now owns 2,792 shares of the company’s stock valued at $127,000 after buying an additional 287 shares in the last quarter. Zurich Insurance Group Ltd FI raised its position in shares of Qiagen by 5.7% during the third quarter. Zurich Insurance Group Ltd FI now owns 5,291 shares of the company’s stock valued at $239,000 after buying an additional 287 shares during the last quarter. National Bank of Canada FI raised its position in shares of Qiagen by 1.2% during the third quarter. National Bank of Canada FI now owns 25,636 shares of the company’s stock valued at $1,155,000 after buying an additional 308 shares during the last quarter. Finally, Atria Investments Inc lifted its holdings in shares of Qiagen by 6.0% in the third quarter. Atria Investments Inc now owns 7,632 shares of the company’s stock worth $348,000 after buying an additional 433 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.